Bioseparation in antibody manufacturing: the good, the bad and the ugly.
about
A Single-use Strategy to Enable Manufacturing of Affordable BiologicsProtein adsorption and transport in polymer-functionalized ion-exchangersIsolation and characterization of chimeric human Fc-expressing proteins using protein a membrane adsorbers and a streamlined workflow.Recent developments in membrane-based separations in biotechnology processes: review.State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation.Functional monolithic platforms: chromatographic tools for antibody purification.Different types of aqueous two-phase systems for biomolecule and bioparticle extraction and purification.Clarification technologies for monoclonal antibody manufacturing processes: Current state and future perspectives.Recombinant protein production by in vivo polymer inclusion display.Continuous counter-current chromatography for capture and polishing steps in biopharmaceutical production.Scale-Up of Protein Purification: Downstream Processing Issues.Feasibility study of semi-selective protein precipitation with salt-tolerant copolymers for industrial purification of therapeutic antibodies.Continuous Manufacturing of Recombinant Therapeutic Proteins: Upstream and Downstream Technologies.A novel 'pipeline' system for downstream preparation of therapeutic monoclonal antibodies.Application of aqueous two-phase micellar system to improve extraction of adenoviral particles from cell lysate.Antibody purification via affinity membrane chromatography method utilizing nucleotide binding site targeting with a small molecule.Charge- and Size-Selective Molecular Separation using Ultrathin Cellulose Membranes.Caprylic acid-induced impurity precipitation from protein A capture column elution pool to enable a two-chromatography-step process for monoclonal antibody purification.Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing.Application of calcium phosphate flocculation in high-density cell culture fluid with high product titer of monoclonal antibody.A novel approach to characterize host cell proteins associated with therapeutic monoclonal antibodies.Modeling of transient flow through a viscoelastic preparative chromatography packing.Advective hydrogel membrane chromatography for monoclonal antibody purification in bioprocessing.Fast and scalable purification of a therapeutic full-length antibody based on process crystallization.Evolving trends in mAb production processes.Comparison of analytical protein separation characteristics for three amine-based capillary-channeled polymer (C-CP) stationary phases.Economics of recombinant antibody production processes at various scales: Industry-standard compared to continuous precipitation.Development of production and purification processes of recombinant fragment of pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences.Study of the conditions for multi-modal chromatographic capture of Fab′ from dual-salt precipitatedE. colihomogenate
P2860
Q26738464-A805B6F0-A81C-4F04-8BB7-D500F2701F4CQ35889111-10854F7A-FA02-42C4-A248-D9A7D4C4D5E4Q37489561-E2B62010-6783-4A54-BBD2-D75CFF0871AEQ37941805-38D7FEE4-FB77-4ED6-B601-276549642A36Q38013999-7E2B466D-5D12-4E5B-B4D9-0350AF185345Q38104707-30D616F5-F7C0-4CED-9823-8A56DD7534EBQ38127392-A4F06F4F-6D25-4C0B-9E73-A414E484AA50Q38572669-2E0AAB58-AC40-45DF-B6E3-C9B64D55D3AEQ38628960-66D6EB06-5340-4ADF-82AE-D45022A49440Q38845449-87CF5F86-0FDD-49D9-A006-C8048F109E21Q38978537-1498CE1F-E64C-433A-9534-CDDD68D21259Q39157543-CD6CBB14-31C1-4647-ABE6-3F52597EA5F9Q39164854-5C8624D1-60E8-4308-971A-7C04299BD03CQ42281844-45CD16EA-08B1-46B1-ADB7-66A02E4EC978Q45875447-91EDC98F-4459-4353-B7A6-3BB981AE8298Q45926628-DA6E9079-2AF7-4EA6-9CF0-CC80DD137D6BQ46472121-F4742956-44A1-40D9-8473-388F8AB1494AQ46683435-97945069-8058-4C86-A56E-76539018FDD0Q46969716-D77A9A8C-F5FA-4C04-B692-BAFD5119647AQ50881776-D2D73CAD-FD39-40F3-8767-FC0EA4D626ADQ51174238-DCF0B290-959A-4699-8B8D-09726F340995Q51195209-DE74303A-5AA7-49F9-BAEE-7CC84F2E0B7BQ51742818-0AA13BC7-9AFC-4C29-8992-3F6AF9A328AEQ51754011-02F5B3B4-83AF-4864-921F-4776B48440C9Q52724995-9C01CA15-693E-4459-B08D-465B14780AB8Q53547434-D87AE68F-C35F-46AA-8750-5AE8480358BEQ53580907-1BD3CE32-C4CD-40E4-AF50-57AB0F7D75F3Q54349086-DFAE13AD-434F-4A36-A9AA-C667FDBACE24Q58338060-6D2D9EC1-2DD0-41C4-8352-4A93CCB54998
P2860
Bioseparation in antibody manufacturing: the good, the bad and the ugly.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bioseparation in antibody manufacturing: the good, the bad and the ugly.
@en
Bioseparation in antibody manufacturing: the good, the bad and the ugly.
@nl
type
label
Bioseparation in antibody manufacturing: the good, the bad and the ugly.
@en
Bioseparation in antibody manufacturing: the good, the bad and the ugly.
@nl
prefLabel
Bioseparation in antibody manufacturing: the good, the bad and the ugly.
@en
Bioseparation in antibody manufacturing: the good, the bad and the ugly.
@nl
P356
P1476
Bioseparation in antibody manufacturing: the good, the bad and the ugly.
@en
P2093
Uwe Gottschalk
P304
P356
10.1021/BP070452G
P577
2008-04-29T00:00:00Z